Amicus Therapeutics, Inc.
FOLDNASDAQHealthcare
$14.49
+$0.00(+0.00%)
Market Cap$4.5B
P/E Ratio—
52W High$14.5
52W Low$5.51
Amicus Therapeutics, Inc. (FOLD) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
FOLD · earnings · updated Jun 8, 2026
Latest Earnings
Q1 FY2026Report Date: Feb 20, 2026EPS Actual
$0.01
Est. $0.07 · -86.0%
Revenue
$0.19B
Est. $0.18B · +2.6%
Fiscal Period
Q1 FY2026
FY ends December
Report Date
Feb 20, 2026
After Market Close
▼ Miss EPS▲ Beat Revenue
FOLD reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.09
Rev. $41.31B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.09
Rev. Est.$41.31B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q2 FY2026 | May 7, 2026 | $0.05 | — | — | — | $0.16B | — |
| ▼ Q1 FY2026 | Feb 20, 2026 | $0.07 | $0.01 | -86.0% | $0.19B | $0.18B | +2.6% |
| ▲ Q4 FY2025 | Nov 4, 2025 | $0.12 | $0.17 | +41.7% | $0.17B | $0.18B | -8.6% |
| ▼ Q3 FY2025 | Jul 31, 2025 | $0.02 | $0.01 | -50.0% | $0.15B | $0.17B | -6.4% |
| ▼ Q2 FY2025 | May 1, 2025 | $0.08 | $0.03 | -62.5% | $0.13B | $0.15B | -15.1% |
| ▲ Q1 FY2025 | Feb 19, 2025 | $0.02 | $0.09 | +350.0% | $0.15B | $0.15B | +1.2% |
| ▲ Q4 FY2024 | Nov 6, 2024 | $0.08 | $0.10 | +25.0% | $0.14B | $0.15B | -4.0% |
| ▲ Q3 FY2024 | Aug 8, 2024 | $0.05 | $0.06 | +9.8% | $0.13B | $0.12B | +4.5% |
Q2 FY2026
May 7, 2026
EPS Actual
—
EPS Est.
$0.05
EPS Surpr.
—
Revenue
—
Q1 FY2026
Feb 20, 2026Miss
EPS Actual
$0.01
EPS Est.
$0.07
EPS Surpr.
-86.0%
Revenue
$0.19B
Q4 FY2025
Nov 4, 2025Beat
EPS Actual
$0.17
EPS Est.
$0.12
EPS Surpr.
+41.7%
Revenue
$0.17B
Q3 FY2025
Jul 31, 2025Miss
EPS Actual
$0.01
EPS Est.
$0.02
EPS Surpr.
-50.0%
Revenue
$0.15B
Q2 FY2025
May 1, 2025Miss
EPS Actual
$0.03
EPS Est.
$0.08
EPS Surpr.
-62.5%
Revenue
$0.13B
Q1 FY2025
Feb 19, 2025Beat
EPS Actual
$0.09
EPS Est.
$0.02
EPS Surpr.
+350.0%
Revenue
$0.15B
Q4 FY2024
Nov 6, 2024Beat
EPS Actual
$0.10
EPS Est.
$0.08
EPS Surpr.
+25.0%
Revenue
$0.14B
Q3 FY2024
Aug 8, 2024Beat
EPS Actual
$0.06
EPS Est.
$0.05
EPS Surpr.
+9.8%
Revenue
$0.13B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.42 | $0.43 | $0.44 | 1 |
| Q3 FY2027 | $0.18 | $0.18 | $0.19 | 1 |
| Q2 FY2027 | $0.13 | $0.13 | $0.13 | 1 |
| Q1 FY2027 | $0.10 | $0.10 | $0.10 | 1 |
| Q4 FY2026 | $0.12 | $0.12 | $0.12 | 1 |
| Q3 FY2026 | $0.10 | $0.11 | $0.11 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.3B | $0.3B | $0.3B | 3 |
| Q3 FY2027 | $0.2B | $0.2B | $0.2B | 2 |
| Q2 FY2027 | $0.2B | $0.2B | $0.2B | 2 |
| Q1 FY2027 | $0.2B | $0.2B | $0.2B | 3 |
| Q4 FY2026 | $0.2B | $0.2B | $0.2B | 3 |
| Q3 FY2026 | $0.2B | $0.2B | $0.2B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q1 FY2026 | Feb 20, 2026 | -86.0% | $14.35 | $14.34 | -0.07% |
| ▲ Q4 FY2025 | Nov 4, 2025 | +41.7% | $8.86 | $8.99 | +1.47% |
| ▼ Q3 FY2025 | Jul 31, 2025 | -50.0% | $6.13 | $5.99 | -2.28% |
| ▼ Q2 FY2025 | May 1, 2025 | -62.5% | $7.68 | $6.68 | -13.02% |
| ▲ Q1 FY2025 | Feb 19, 2025 | +350.0% | $9.85 | $9.56 | -2.94% |
| ▲ Q4 FY2024 | Nov 6, 2024 | +25.0% | $11.74 | $11.24 | -4.26% |
| ▲ Q3 FY2024 | Aug 8, 2024 | +9.8% | $10.00 | $11.32 | +13.20% |
| ▲ Q2 FY2024 | May 9, 2024 | +66.7% | $10.14 | $9.48 | -6.51% |
Q1 FY2026-0.07%
Report Date
Feb 20, 2026
EPS Beat/Miss
-86.0%
Price Before
$14.35
Price After
$14.34
Q4 FY2025+1.47%
Report Date
Nov 4, 2025
EPS Beat/Miss
+41.7%
Price Before
$8.86
Price After
$8.99
Q3 FY2025-2.28%
Report Date
Jul 31, 2025
EPS Beat/Miss
-50.0%
Price Before
$6.13
Price After
$5.99
Q2 FY2025-13.02%
Report Date
May 1, 2025
EPS Beat/Miss
-62.5%
Price Before
$7.68
Price After
$6.68
Q1 FY2025-2.94%
Report Date
Feb 19, 2025
EPS Beat/Miss
+350.0%
Price Before
$9.85
Price After
$9.56
Q4 FY2024-4.26%
Report Date
Nov 6, 2024
EPS Beat/Miss
+25.0%
Price Before
$11.74
Price After
$11.24
Q3 FY2024+13.20%
Report Date
Aug 8, 2024
EPS Beat/Miss
+9.8%
Price Before
$10.00
Price After
$11.32
Q2 FY2024-6.51%
Report Date
May 9, 2024
EPS Beat/Miss
+66.7%
Price Before
$10.14
Price After
$9.48
Avg Beat Reaction+0.19%
Avg Miss Reaction-5.12%
Beat Rate5 / 8 quarters
Largest Move+13.20% (Q3 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: FOLD ends December
Amicus Therapeutics, Inc. (FOLD) most recently reported earnings on February 20, 2026 for Q1 FY2026, posting EPS of $0.01 — missing the analyst consensus of $0.07 by -86.0%. The next FOLD earnings date is expected around September 1, 2026.
Each quarter, investors track FOLD earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. FOLD revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
FOLD's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
FOLD earnings · 5 questionsAmicus Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. FOLD typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; FOLD historically reports after market close (AMC).
FOLD earnings datewhen is FOLD earningsFOLD next earnings datewhen does FOLD report earningsFOLD earnings calendar
▸ Source: FMP · Amicus Therapeutics, Inc. SEC filings · US GAAP · Amicus Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026